FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2057871445> ?p ?o ?g. }

• W2057871445 endingPage "2965" @default.
• W2057871445 startingPage "2959" @default.
• W2057871445 abstract "Fifteen patients with Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML) who were ineligible for allogeneic bone marrow transplantation (BMT) or alpha-interferon therapy were included in this study. Eight patients were in the first late chronic phase, five were in the second chronic phase, one was in the accelerated phase, and one was in the blastic phase. Autologous bone marrow cells (median, 2.5 × 108 nucleated cells/kg) were stored at a median of 30 months after diagnosis. Patients were treated with cyclophosphamide (1.5 g/m2 daily for 4 days), carmustine (BCNU) (300 mg/m2), and etoposide (VP-16) (250 mg/m2 daily for 3 days) (CBV), followed by reinfusion of autologous bone marrow. Hematopoietic recovery was rapid, and toxicity was mild to moderate in 14 patients. One patient died of cytomegalovirus pneumonitis. Eight of 15 patients showed Ph suppression to less than 90% Ph-positive metaphases after autologous BMT. Major cytogenetic responses (Ph suppression to less than 35% Ph-positive metaphases) developed in four patients. Cytogenetic responses were observed in 4 of 11 patients infused with 100% Ph-positive marrows, and in all 4 patients infused with Ph-mosaic marrows (mixture of diploid and Ph-positive cells). Better results were observed when autologous BMT was performed in the chronic phase compared with the advanced phases. The major cytogenetic responses have lasted for 3, 4, 12, and 15+ months, whereas minor cytogenetic responses lasted for only a short time (less than 2 months). Three of seven patients (43%) in the chronic phase with previous resistance to alpha-interferon therapy became sensitive to alpha-interferon therapy after autologous BMT. The authors concluded that intensive chemotherapy followed by autologous BMT produced cytogenetic remissions in patients with Ph-positive CML and reinduced disease sensitivity to alpha-interferon therapy in patients previously resistant to it. This is particularly useful when treatment is given during the chronic phase and stem cells are collected at a time of previous cytogenetic remission." @default.
• W2057871445 created "2016-06-24" @default.
• W2057871445 creator A5000106724 @default.
• W2057871445 creator A5003495097 @default.
• W2057871445 creator A5011173909 @default.
• W2057871445 creator A5011529063 @default.
• W2057871445 creator A5021295987 @default.
• W2057871445 creator A5028046297 @default.
• W2057871445 creator A5052894313 @default.
• W2057871445 creator A5081284360 @default.
• W2057871445 creator A5090435894 @default.
• W2057871445 date "1991-06-15" @default.
• W2057871445 modified "2023-10-16" @default.
• W2057871445 title "Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of philadelphia chromosome-negative cells in chronic myelogenous leukemia" @default.
• W2057871445 cites W110083684 @default.
• W2057871445 cites W1964445294 @default.
• W2057871445 cites W1994954403 @default.
• W2057871445 cites W1996285570 @default.
• W2057871445 cites W1998593414 @default.
• W2057871445 cites W2039978091 @default.
• W2057871445 cites W2042304936 @default.
• W2057871445 cites W2060620536 @default.
• W2057871445 cites W2076372887 @default.
• W2057871445 cites W2081807657 @default.
• W2057871445 cites W2085307511 @default.
• W2057871445 cites W2122455557 @default.
• W2057871445 cites W2167541030 @default.
• W2057871445 cites W2328885996 @default.
• W2057871445 cites W2339475636 @default.
• W2057871445 cites W2402092920 @default.
• W2057871445 cites W2596224382 @default.
• W2057871445 doi "https://doi.org/10.1002/1097-0142(19910615)67:12<2959::aid-cncr2820671203>3.0.co;2-t" @default.
• W2057871445 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1675151" @default.
• W2057871445 hasPublicationYear "1991" @default.
• W2057871445 type Work @default.
• W2057871445 sameAs 2057871445 @default.
• W2057871445 citedByCount "31" @default.
• W2057871445 crossrefType "journal-article" @default.
• W2057871445 hasAuthorship W2057871445A5000106724 @default.
• W2057871445 hasAuthorship W2057871445A5003495097 @default.
• W2057871445 hasAuthorship W2057871445A5011173909 @default.
• W2057871445 hasAuthorship W2057871445A5011529063 @default.
• W2057871445 hasAuthorship W2057871445A5021295987 @default.
• W2057871445 hasAuthorship W2057871445A5028046297 @default.
• W2057871445 hasAuthorship W2057871445A5052894313 @default.
• W2057871445 hasAuthorship W2057871445A5081284360 @default.
• W2057871445 hasAuthorship W2057871445A5090435894 @default.
• W2057871445 hasBestOaLocation W20578714451 @default.
• W2057871445 hasConcept C104317684 @default.
• W2057871445 hasConcept C126322002 @default.
• W2057871445 hasConcept C138626823 @default.
• W2057871445 hasConcept C141071460 @default.
• W2057871445 hasConcept C142724271 @default.
• W2057871445 hasConcept C203014093 @default.
• W2057871445 hasConcept C2776694085 @default.
• W2057871445 hasConcept C2776755627 @default.
• W2057871445 hasConcept C2776960273 @default.
• W2057871445 hasConcept C2778119113 @default.
• W2057871445 hasConcept C2778461978 @default.
• W2057871445 hasConcept C2778904597 @default.
• W2057871445 hasConcept C2780007613 @default.
• W2057871445 hasConcept C2780147359 @default.
• W2057871445 hasConcept C2911091166 @default.
• W2057871445 hasConcept C55493867 @default.
• W2057871445 hasConcept C71924100 @default.
• W2057871445 hasConcept C86803240 @default.
• W2057871445 hasConcept C90924648 @default.
• W2057871445 hasConceptScore W2057871445C104317684 @default.
• W2057871445 hasConceptScore W2057871445C126322002 @default.
• W2057871445 hasConceptScore W2057871445C138626823 @default.
• W2057871445 hasConceptScore W2057871445C141071460 @default.
• W2057871445 hasConceptScore W2057871445C142724271 @default.
• W2057871445 hasConceptScore W2057871445C203014093 @default.
• W2057871445 hasConceptScore W2057871445C2776694085 @default.
• W2057871445 hasConceptScore W2057871445C2776755627 @default.
• W2057871445 hasConceptScore W2057871445C2776960273 @default.
• W2057871445 hasConceptScore W2057871445C2778119113 @default.
• W2057871445 hasConceptScore W2057871445C2778461978 @default.
• W2057871445 hasConceptScore W2057871445C2778904597 @default.
• W2057871445 hasConceptScore W2057871445C2780007613 @default.
• W2057871445 hasConceptScore W2057871445C2780147359 @default.
• W2057871445 hasConceptScore W2057871445C2911091166 @default.
• W2057871445 hasConceptScore W2057871445C55493867 @default.
• W2057871445 hasConceptScore W2057871445C71924100 @default.
• W2057871445 hasConceptScore W2057871445C86803240 @default.
• W2057871445 hasConceptScore W2057871445C90924648 @default.
• W2057871445 hasIssue "12" @default.
• W2057871445 hasLocation W20578714451 @default.
• W2057871445 hasLocation W20578714452 @default.
• W2057871445 hasOpenAccess W2057871445 @default.
• W2057871445 hasPrimaryLocation W20578714451 @default.
• W2057871445 hasRelatedWork W1979697139 @default.
• W2057871445 hasRelatedWork W1987997012 @default.
• W2057871445 hasRelatedWork W2005774754 @default.
• W2057871445 hasRelatedWork W2057871445 @default.
• W2057871445 hasRelatedWork W2199047065 @default.
• W2057871445 hasRelatedWork W2281287090 @default.
• W2057871445 hasRelatedWork W2398620837 @default.

• next